-
You must submit the settlement "Proof" form attached below, in order to participate in this settlement. There is a strict deadline of September 16, 2020 by which all claims must be submitted. The instructions for submitting are included in the "Proof" and the "Notice" files attached below for your download. DO NOT SEND THE FORMS TO THE SHAREHOLDERS FOUNDATION, FOLLOW THE DIRECTIONS IN THE "PROOF".
-
To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Lawsuit Overview
Settlement Overview
You must register to view and download the Settlement Notice and Settlement Proof.
May 27, 2020 - The court preliminarily approved the settlement.
February 6, 2020 - An amended stipulation of settlement was filed by the parties.
December 20, 2019 - The court denied the preliminary approval of the settlement.
December 11, 2019 - A stipulation of settlement was filed by the parties.
October 1, 2019 - An amended consolidated complaint was filed.
September 5, 2019 - The court granted the defendants' motion to dismiss. The plaintiffs were given leave to amend the complaint.
February 6, 2019 - A motion to dismiss the consolidated complaint was filed.
December 22, 2017 - A consolidated complaint was filed.
January 31, 2017 (Shareholders Foundation) - An investor in shares of Regulus Therapeutics Inc (NASDAQ:RGLS) filed a lawsuit in the U.S. District Court for the Southern District of California over alleged violations of Federal Securities Laws by Regulus Therapeutics Inc in connection with certain allegedly false and misleading statements made between January 21, 2016 and June 27, 2016 According to the complaint the plaintiff alleges on behalf of purchasers of Regulus Therapeutics Inc (NASDAQ:RGLS) common shares between January 21, 2016 and June 27, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between January 21, 2016 and June 27, 2016 the Defendants made false and/or misleading statements and/or failed to disclose that patients treated with RG-101 were at increased risk of contracting jaundice, that consequently, the Company had overstated RG-101’s approval prospects and/or commercial viability, and that as a result of the foregoing, Regulus’s public statements were materially false and misleading at all relevant times. Regulus Therapeutics Inc reported that its annual Total Revenue rose from $7.67 million in 2014 to $20.76 million in 2015 and that its Net Loss declined from $56.68 million in 2014 to $55.75 million in 2015. Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) reached as high as $22.08 per share in 2014 and as high as $20.70 per share in 2015. On June 27, 2016, Regulus Therapeutics Inc announced during aftermarket hours that it received verbal notice from the U.S. Food and Drug Administration (“FDA”) that the FDA had placed the Regulus Therapeutics’ investigational new drug for the treatment of chronic hepatitis C virus infection on clinical hold after a second serious adverse event of jaundice was reported. Shares of Regulus Therapeutics Inc declined on June 28, 2016 to as low as $2.44 per share.